Meeder Advisory Services Inc. Takes Position in Becton, Dickinson and Company $BDX

Meeder Advisory Services Inc. purchased a new position in Becton, Dickinson and Company (NYSE:BDX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 3,323 shares of the medical instruments supplier’s stock, valued at approximately $503,000.

Several other institutional investors also recently added to or reduced their stakes in BDX. Larson Financial Group LLC boosted its stake in Becton, Dickinson and Company by 1.7% in the fourth quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock valued at $627,000 after acquiring an additional 53 shares during the last quarter. Camelot Portfolios LLC increased its stake in shares of Becton, Dickinson and Company by 1.5% during the 4th quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier’s stock worth $688,000 after purchasing an additional 54 shares during the last quarter. Atlantic Union Bankshares Corp raised its holdings in shares of Becton, Dickinson and Company by 0.9% in the 4th quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock worth $1,185,000 after purchasing an additional 57 shares during the period. WPG Advisers LLC lifted its stake in Becton, Dickinson and Company by 64.2% in the fourth quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 61 shares during the last quarter. Finally, Oakworth Capital Inc. lifted its stake in Becton, Dickinson and Company by 4.3% in the fourth quarter. Oakworth Capital Inc. now owns 1,555 shares of the medical instruments supplier’s stock valued at $302,000 after purchasing an additional 64 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on BDX shares. Jefferies Financial Group restated a “buy” rating and issued a $210.00 target price on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Wells Fargo & Company lifted their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. UBS Group started coverage on Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price objective on the stock. The Goldman Sachs Group dropped their price objective on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a report on Wednesday, May 27th. Finally, Barclays lifted their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Becton, Dickinson and Company presently has an average rating of “Hold” and a consensus target price of $185.67.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. This trade represents a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 11,779 shares of company stock valued at $1,974,669 in the last three months. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.1%

Shares of NYSE BDX opened at $187.79 on Friday. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The company has a market cap of $51.74 billion, a P/E ratio of 56.56, a P/E/G ratio of 13.22 and a beta of 0.19. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $190.01. The business has a 50-day simple moving average of $160.66 and a two-hundred day simple moving average of $160.91.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the prior year, the firm posted $3.68 earnings per share. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Research analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be paid a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is currently 126.51%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.